Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed invasive breast cancer meeting the following criteria:

  * Early-stage disease

    * No stage IV disease
  * More than one synchronous primary breast tumor
  * Lymph node positive OR high-risk lymph node negative
* Candidate for treatment with anthracycline- and taxane-based chemotherapy in the adjuvant setting

  * Must begin therapy within 84 days after the final required surgical procedure
* HER2/neu-negative breast cancer, defined as an immunohistochemistry (IHC) score of 0, 1+ or 2+ and fluorescent in situ hybridization (FISH) not amplified
* No CNS disease (e.g., primary brain tumor or brain metastasis)
* Hormone receptor status known

PATIENT CHARACTERISTICS:

* Male or female
* Pre- or post-menopausal
* ECOG performance status 0-1
* Absolute neutrophil count ≥ 1,000/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Bilirubin normal
* AST or ALT ≤ 2.5 times upper limit of normal
* Creatinine normal OR creatinine clearance ≥ 60 mL/min
* Urine protein:creatinine ratio ≤ 1.0
* PT and PTT normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 6 months after completion of study therapy
* LVEF normal by MUGA scan at baseline
* No significant bleeding within the past 6 months
* No uncontrolled underlying bleeding diathesis
* No nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy, including any of the following conditions:

  * Blood pressure \> 150/100 mm Hg
  * Unstable angina
  * New York Heart Association class II -IV congestive heart failure
  * Myocardial infarction or stroke within the past 12 months
  * Clinically significant peripheral vascular disease
* No seizures not controlled with standard medical therapy
* No history of stroke
* No known allergy or hypersensitivity to study drugs (prior hypersensitivity to paclitaxel allowed)
* No significant traumatic injury within the past 28 days
* No serious nonhealing wound, ulcer, or bone fracture
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* No active gastroduodenal ulcer
* No uncontrolled intercurrent illness, including psychiatric illness or social situation that would limit compliance with study requirements

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior therapy for an ipsilateral or contralateral breast cancer primary allowed provided the following criteria are met:

  * No prior anthracycline therapy
  * Prior hormonal therapy for this previous breast cancer is allowed, but must be stopped during study therapy
  * At least 1 year since prior taxane therapy
* More than 28 days since prior and no concurrent major surgery or open biopsy

  * Anticipated reconstructive surgery (e.g., tissue expander exchange) is allowed during the course of the study (bevacizumab will be held during that time as per protocol guidelines)
* More than 7 days since prior minor surgery, including fine-needle aspiration or core biopsy

  * At least 24 hours since prior indwelling catheter placement
* No prior bevacizumab or other KDR inhibitors (e.g., VEGF Trap, semaxanib, SU6668, vandetanib, vatalanib, AEE788, or IMC-1CII)
* No concurrent full-dose anticoagulation therapy
* No concurrent hormonal therapy as chemoprevention
* Concurrent participation in adjuvant hormone therapy or correlative or companion (e.g., bisphosphonate clinic) studies allowed
* No other concurrent anticancer therapy